Portal de Periódicos da CAPES

The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors

2021; Massachusetts Medical Society; Volume: 384; Issue: 12 Linguagem: Inglês

10.1056/nejmc2031965

1533-4406

Benoı̂t Rousseau, Michael B. Foote, Steven B. Maron, Bill H. Diplas, Steve Lu, Guillem Argilés, Andrea Cercek, Luis A. Díaz,

Lung Cancer Treatments and Mutations

Immune Checkpoint Inhibitors and Tumor Mutational Burden The FDA has approved immune checkpoint inhibitors for solid tumors of any histologic origin with more than 10 mutations per megabase of DNA....